Figure 1. Itraconazole has antiviral activity against HRV in vitro.

(A) Cell viability was evaluated based on results of the SRB assay. HeLa cells were infected at the 50% cell culture infective dose (CCID₅₀) of HRV1B and treated with indicated concentrations of ICZ. Cell viability was determined based on absorbance at 520 nm. (B) Relative HRV gene expression in control, HRV1B-infected, and 10 μm ICZ-treated cells by real-time PCR. (C-a) Control cells; (C-b) 10 μm and (C-c) 50 μm ICZ-treated cells; (C-d) HRV1B-infected cells; (C-e) 10 μm and (C-f) 50 μm ICZ-treated cells infected with HRV1B. (D) Cell viability was evaluated based on results of the SRB assay. HeLa ells were infected at the CCID₅₀ of HRV14 and HRV15 and treated with indicated concentrations of ICZ. Cell viability was determined based on absorbance at 520 nm. Bar graphs show mean ± SEM. ^∗∗P < 0.01, ^∗∗∗P < 0.001, Newman-Keuls multiple comparisons test (analysis of variance).